Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Global dementia prevalence is expected to increase to 152 million in 2050, a 204% increase compared to 2018.

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

SEPTEMBER 23, 2024

The research underpinning the CTLA-4 and PD-1 technologies resulted in the Nobel Prize in Physiology or Medicine 2018 for the researchers and teams who pioneered them – James Allison of the University of California, Berkeley, and Tasuku Honjo at Kyoto University, respectively.

RNA 173

RNA Immune Response Small Molecule Treatment 173

Drug Discovery World

AUGUST 8, 2024

DDW Editor Reece Armstrong speaks to Roger Levy , Global Medical Expert Immunology & Specialty Medicine at GSK about the company’s work into treating systemic sclerosis-associated interstitial lung disease and its recent BLISSc-ILD study evaluating its belimumab treatment.

Disease 147

Disease Clinical Trials Treatment Trials 147

Drug Discovery World

JULY 2, 2024

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM).

Virus 147

Virus Trials Clinical Trials Laboratories 147

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

The Pharma Data

NOVEMBER 19, 2020

2010 to 2018 Saw Decrease in Rate of Death for People With HIV. 19, 2020 — From 2010 to 2018, there was a 36.6 Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. percent overall during 2010 to 2018 (from 19.4 Professional. THURSDAY, Nov. 20 issue of the U.S. Bosh, Ph.D., to 8.5). .

Treatment 52

Treatment Disease Research 52

FDA Law Blog: Drug Discovery

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Disease 59

Disease Production FDA Drug Development 59

Drug Discovery World

DECEMBER 18, 2023

Casgevy The committee recommended granting a conditional marketing authorisation for Casgevy (exagamglogene autotemcel), an advanced therapy medicinal product (ATMP) for the treatment of transfusion dependent beta-thalassemia and severe sickle cell disease.

Drugs 130

Drugs Therapies Treatment Disease 130

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . adults have been diagnosed with dry eye disease, a chronic, episodic, multifactorial disease. It also increases your risk for inflamed cornea, cornea eye disease, corneal ulcers and injuries, and eye infections. .

FDA 52

FDA Disease Treatment FDA Approval 52

Conversations in Drug Development Trends

FEBRUARY 28, 2023

95% of rare diseases don’t have a treatment approved and won’t anytime soon. Miraculously, there was an approved treatment. This treatment only exists because a small charity in the ’70s donated the funds needed for the researcher to discover it. Uplifting Athletes (UA) is on a mission to change that. It saved my life.”

Clinical Trials 52

Clinical Trials Disease Trials Research 52

Drug Target Review

JULY 13, 2023

Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. Dewpoint Therapeutics, a platform drug discovery company founded in 2018, has been at the forefront of this exciting field. Klein notes the importance of Dewpoint’s disease-agnostic approach.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

Drug Discovery World

DECEMBER 5, 2022

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders. . Understanding rare diseases remains a significant challenge. Understanding rare diseases remains a significant challenge.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

New Drug Approvals

SEPTEMBER 23, 2024

Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. SCHEME PATENT PTC Therapeutics Inc., Audiol Res. 2020-01-02. 2020-01-02.

Small Molecule 57

Small Molecule RNA DNA Disease 57

Drug Discovery World

SEPTEMBER 1, 2023

The new therapeutics companies BII has accepted into the Venture Lab acceleration programme are: Loma Therapeutics, which is developing targeted immunotherapy for efficient and safe treatment of patients with HPV infection, dysplasia, and cancer. Since its inception in 2018, BII has supported 87 start-ups and projects.

Laboratories 130

Laboratories Disease Therapies Treatment 130

Drug Discovery World

OCTOBER 9, 2023

Despite the size of the market and the global impact, there are currently no effective treatments. DS: As new variants begin circulating, what impact could this finding have on our understanding and the potential treatment of long Covid? DS: Why do you think we are no closer to treatments for long Covid?

Drug Development 147

Drug Development Clinical Trials Virus Drugs 147

Drug Discovery World

JANUARY 31, 2023

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS. Best supportive care usually includes salvage chemotherapy, which is given after the cancer has not responded to other treatments.

Therapies 130

Therapies Clinical Trials Treatment Trials 130

Drug Discovery World

MARCH 17, 2023

Since 2018, GARDP and the University of Liverpool have been working together to advance new treatment options for new-borns with sepsis. New treatment options are needed to respond to growing drug resistance to the current WHO-recommended regimen, especially in many low- and middle-income countries.

Clinical Trials 130

Clinical Trials Trials Research Treatment 130

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. In my case, my daughter Iris has GM1 gangliosidosis.

Disease 52

Disease Clinical Trials Trials Treatment 52

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. They could be spread by physical contact, airborne, waterborne, foodborne, or vector-borne.

Drugs 111

Drugs RNA DNA Disease 111

Drug Discovery World

SEPTEMBER 26, 2022

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product. . 2018; 9: 1595. Official comments . Varricchi G, et al. Li Y, et al.

Clinical Trials 130

Clinical Trials Trials Disease Production 130

The Pharma Data

APRIL 17, 2021

Biogen’s expansion in China now includes treatment options approved for relapsing MS and spinal muscular atrophy. today announced that China’s National Medical Products Administration (NMPA) has approved TECFIDERA ® (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS).

Treatment 52

Treatment Clinical Trials Disease Trials 52

The Pharma Data

NOVEMBER 2, 2020

The World Health Organization’s (WHO) Global TB Programme welcomes the results from an important study on shortened treatment for drug-susceptible tuberculosis (TB) in children, presented at the 51 st virtual Union World Conference on Lung Health. Side-effects related to treatment were few, and similar across both groups.

Treatment 52

Treatment Trials Clinical Trials International 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. Based on these data, ADT alone should no longer be considered sufficient for patients with advanced, castration-sensitive disease.”. About ERLEADA ® (apalutamide).

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

Drug Discovery World

OCTOBER 2, 2023

Artificial intelligence (AI) is rapidly taking hold in the healthcare sector 1 , including in medical imaging, where AI often targets screening, patient eligibility, detection and disease response (Figure 1). This can lead to generation of more objective endpoints that might lead to a better assessment of treatment efficacy.

Clinical Trials 147

Clinical Trials Trials Treatment Drug Trials 147

Common Sense for Drug Policy Blog

JANUARY 5, 2024

of the US adult population, injected drugs in 2018. Much of this increase is likely attributable to increases in IDU, but it is important to consider methodological differences in the creation of this 2018 estimate vs the 2011 estimate. million PWID in 2011, which suggest the 2018 estimate is closer to 3 times higher than in 2011.

Drugs 40

Drugs Treatment Disease Therapies 40

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

The Pharma Data

NOVEMBER 18, 2021

Eli Lilly and Company blazoned that registration is now open for the CHALLENGE-MIG clinical trial, the first and only head-to- head trial comparing twoanti-calcitonin gene- related peptide (CGRP) drugs for the preventative treatment of episodic migraine in grown-ups.1 gepants) may help people achieve the pretensions that count most to them.

Treatment 52

Treatment Clinical Trials Trials FDA 52

The Pharma Data

MAY 5, 2022

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia. At Janssen, we’re creating a future where disease is a thing of the past. About Acute Myeloid Leukemia. About the Janssen Pharmaceutical Companies of Johnson & Johnson.

Disease 52

Disease Drug Development Clinical Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 7, 2020

based clinical trials investigating interventions for high blood pressure between 2009-2018, just 52 were exclusively in Black people. While the numbers grew over that decade – from 3.9% (3 of 77 trials) in 2009 to 6.2% (9 of 146) in 2018 – the increase was not enough to be statistically significant.

Treatment 52

Treatment Clinical Trials Trials Doctors 52

The Pharma Data

MARCH 16, 2022

The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessment EMPA-KIDNEY is the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease to date Detailed results are expected to be presented later this year.

Trials 52

Trials Disease Hospitals Clinical Trials 52

PLOS: DNA Science

MARCH 21, 2024

million price tag for the one-time infusion, and for the older siblings who contributed to developing the gene treatment, but were too sick to receive it. The history of gene therapy for MLD is compelling – DNA Science covered it for Rare Disease Day in 2021, here. She passed away in 2013.

Therapies 89

Therapies Clinical Trials DNA Trials 89

The Pharma Data

DECEMBER 3, 2020

3, 2020 (American Heart Association News) — Your chances of dying from heart disease or stroke are higher if you live in a county considered socially vulnerable due to factors such as poverty, crowded housing and poor access to transportation, new research shows. THURSDAY, Dec. More than 1 in 3 U.S.

Disease 52

Disease Research Treatment 52

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Treatment 52

Treatment DNA Trials Therapies 52

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. A market research report published in late June 2018 by HTF market Intelligence Consulting suggested that the ADC market in China would grow exponentially by 2023 4.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

The Pharma Data

JUNE 29, 2021

ENSPRYNG is the first and only NMOSD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training. Importantly, people with NMOSD now have the flexibility to administer treatment at home, which may alleviate the need to travel for hospital appointments.”.

Treatment 52

Treatment Therapies Disease Clinical Development 52

Advarra

JULY 26, 2022

The 2018 Farm Bill. The 2018 Farm Bill removed hemp from the Controlled Substance Act. Importantly, the 2018 Farm Bill preserved FDA authority to regulate products with cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic (FD&C) Act and Section 351 of the Public Health Service Act.

Regulations 97

Regulations Research FDA FDA Approval 97